AR112419A1 - Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos - Google Patents
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerposInfo
- Publication number
- AR112419A1 AR112419A1 ARP180101511A AR112419A1 AR 112419 A1 AR112419 A1 AR 112419A1 AR P180101511 A ARP180101511 A AR P180101511A AR 112419 A1 AR112419 A1 AR 112419A1
- Authority
- AR
- Argentina
- Prior art keywords
- heavy chain
- antibodies
- wild
- hetero
- target
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Se refiere a anticuerpos monoclonales biespecíficos bivalentes (bbmAb) o variantes de los mismos, y a métodos para fabricar dichos anticuerpos mediante la coexpresión de derivados modificados mutados con Fc de dos anticuerpos monoclonales diferentes en líneas celulares de mamíferos. Reivindicación 1: Un anticuerpo biespecífico adecuado para la coexpresión en una célula hospedadora común, en donde el anticuerpo comprende a) una primera parte que es una inmunoglobulina con una primera cadena ligera variable de tipo salvaje lambda (VL1) y una primera cadena pesada variable de tipo salvaje (VH1), que se une específicamente a un primer objetivo, y una primera cadena pesada constante (CH1) con una modificación de hetero-dimerización, y b) una segunda parte que es una inmunoglobulina con una segunda cadena ligera variable de tipo salvaje kappa (VL2) y una segunda cadena pesada variable de tipo salvaje (VH2), que se une específicamente a un segundo objetivo, diferente del primer objetivo, y una segunda cadena pesada constante (CH2) con una modificación de hetero-dimerización que es complementaria a la modificación de hetero-dimerización de la primera cadena pesada constante, donde la primera parte y la segunda parte, cuando se coexpresan en una célula hospedadora común, forman un anticuerpo biespecífico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762518090P | 2017-06-12 | 2017-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112419A1 true AR112419A1 (es) | 2019-10-30 |
Family
ID=62948274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101511 AR112419A1 (es) | 2017-06-12 | 2018-06-06 | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
Country Status (25)
Country | Link |
---|---|
US (2) | US20190002589A1 (es) |
EP (1) | EP3638692A1 (es) |
JP (2) | JP7106234B2 (es) |
KR (2) | KR102633368B1 (es) |
CN (1) | CN110730788A (es) |
AR (1) | AR112419A1 (es) |
AU (2) | AU2018284303B2 (es) |
BR (1) | BR112019025904A2 (es) |
CA (1) | CA3061097A1 (es) |
CL (1) | CL2019003613A1 (es) |
CO (1) | CO2019013838A2 (es) |
CR (1) | CR20190558A (es) |
CU (1) | CU20190100A7 (es) |
EA (1) | EA201992670A1 (es) |
EC (1) | ECSP19087580A (es) |
IL (1) | IL271179A (es) |
JO (1) | JOP20190283B1 (es) |
MA (1) | MA49394A (es) |
MX (1) | MX2019015021A (es) |
PE (1) | PE20200384A1 (es) |
SG (1) | SG10201913536TA (es) |
TW (1) | TWI826377B (es) |
UY (1) | UY37758A (es) |
WO (1) | WO2018229612A1 (es) |
ZA (1) | ZA201906757B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
CN105820251B (zh) * | 2015-01-08 | 2019-10-15 | 江苏康宁杰瑞生物制药有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
KR20180069839A (ko) | 2015-10-08 | 2018-06-25 | 자임워크스 인코포레이티드 | 카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도 |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
BR112020009889A2 (pt) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acionador e controlador de transdutor acústico |
US20210371511A1 (en) * | 2018-05-09 | 2021-12-02 | Novartis Ag | Use of canakinumab |
CN111018969A (zh) * | 2019-12-27 | 2020-04-17 | 上海药明生物技术有限公司 | 采用轻链select联合层析色谱纯化双特异性抗体的方法 |
CN115066258A (zh) * | 2020-02-28 | 2022-09-16 | 上海药明生物技术有限公司 | 双特异性抗体的纯化 |
KR20230110291A (ko) * | 2020-11-18 | 2023-07-21 | 노파르티스 아게 | Nlrc4-gof 염증복합체병증의 치료에 사용하기 위한 이중특이적 항체 |
WO2022269451A1 (en) | 2021-06-22 | 2022-12-29 | Novartis Ag | Bispecific antibodies for use in treatment of hidradenitis suppurativa |
CN113980135B (zh) * | 2021-12-27 | 2022-04-19 | 三优生物医药(上海)有限公司 | 一种结合冠状病毒双特异性抗体的抗药抗体及其制备方法和应用 |
WO2023209568A1 (en) * | 2022-04-26 | 2023-11-02 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
KR100254759B1 (ko) | 1992-01-23 | 2000-05-01 | 플레믹 크리스티안 | 단량체 및 이량체 항체-단편 융합 단백질 |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US20030148463A1 (en) * | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
DE60139720D1 (de) | 2000-06-28 | 2009-10-08 | Glycofi Inc | Verfahren für die Herstellung modifizierter Glykoproteine |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
ES2442615T5 (es) | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
RU2009148597A (ru) * | 2007-05-29 | 2011-07-10 | Новартис АГ (CH) | Новые показания к применению при лечении антителами против il-1-бета |
US20110045536A1 (en) | 2007-12-21 | 2011-02-24 | Novartis Ag | Mammalian expression vector |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
CN102197136B (zh) | 2008-08-28 | 2016-09-28 | 诺华股份有限公司 | 通过终止密码子连读的多肽同种型的细胞表面展示 |
PL2401383T3 (pl) | 2009-02-27 | 2014-02-28 | Novartis Ag | Sposoby selekcji komórek eukariotycznych wykazujących ekspresję heterologicznego białka |
PT2401377T (pt) * | 2009-02-27 | 2016-08-18 | Novartis Ag | Sistema de vectores de expressão compreendendo dois marcadores de selecção |
WO2011116387A1 (en) * | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
SG184427A1 (en) | 2010-04-20 | 2012-11-29 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
RU2608640C2 (ru) | 2010-08-16 | 2017-01-23 | Новиммун С.А. | Способы получения мультиспецифичных и мультивалентных антител |
LT2771364T (lt) | 2011-10-27 | 2019-09-10 | Genmab A/S | Heterodimerinių baltymų gamyba |
PT2794905T (pt) * | 2011-12-20 | 2020-06-30 | Medimmune Llc | Polipéptidos modificados para estrutura de anticorpos bispecíficos |
JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
CN110981964B (zh) | 2013-01-14 | 2023-09-15 | Xencor股份有限公司 | 新型异二聚体蛋白 |
MA38396B1 (fr) | 2013-03-15 | 2019-05-31 | Novartis Ag | Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit |
EP3936521A1 (en) | 2013-03-15 | 2022-01-12 | Xencor, Inc. | Heterodimeric proteins |
CN106029691A (zh) | 2013-12-20 | 2016-10-12 | 诺华股份有限公司 | 用于重组表达感兴趣产物的新型真核细胞和方法 |
WO2015092735A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Novel eukaryotic cells and methods for recombinantly expressing a product of interest |
GB201414823D0 (en) * | 2014-08-20 | 2014-10-01 | Argen X Bv | Multispecific antibodies |
CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
PE20171103A1 (es) | 2014-11-26 | 2017-08-07 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38 |
US20160176969A1 (en) | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
EP3265010B1 (en) | 2015-03-05 | 2022-11-02 | Think Surgical, Inc. | Methods for locating and tracking a tool axis |
PE20180188A1 (es) | 2015-05-08 | 2018-01-23 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
WO2017011773A2 (en) | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
KR20180069839A (ko) | 2015-10-08 | 2018-06-25 | 자임워크스 인코포레이티드 | 카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도 |
CA3036564A1 (en) * | 2016-09-23 | 2018-03-29 | Elstar Therapeutics, Inc. | Multispecific antibody molecules comprising lambda and kappa light chains |
-
2018
- 2018-06-05 UY UY0001037758A patent/UY37758A/es unknown
- 2018-06-06 AR ARP180101511 patent/AR112419A1/es unknown
- 2018-06-08 MA MA049394A patent/MA49394A/fr unknown
- 2018-06-08 TW TW107119828A patent/TWI826377B/zh active
- 2018-06-08 CU CU2019000100A patent/CU20190100A7/es unknown
- 2018-06-08 EP EP18742595.4A patent/EP3638692A1/en active Pending
- 2018-06-08 AU AU2018284303A patent/AU2018284303B2/en active Active
- 2018-06-08 JP JP2019567724A patent/JP7106234B2/ja active Active
- 2018-06-08 CR CR20190558A patent/CR20190558A/es unknown
- 2018-06-08 KR KR1020227042678A patent/KR102633368B1/ko active IP Right Grant
- 2018-06-08 BR BR112019025904-0A patent/BR112019025904A2/pt unknown
- 2018-06-08 CA CA3061097A patent/CA3061097A1/en active Pending
- 2018-06-08 PE PE2019002532A patent/PE20200384A1/es unknown
- 2018-06-08 EA EA201992670A patent/EA201992670A1/ru unknown
- 2018-06-08 JO JOP/2019/0283A patent/JOP20190283B1/ar active
- 2018-06-08 WO PCT/IB2018/054140 patent/WO2018229612A1/en active Application Filing
- 2018-06-08 KR KR1020197036605A patent/KR20200005746A/ko not_active IP Right Cessation
- 2018-06-08 CN CN201880036745.XA patent/CN110730788A/zh active Pending
- 2018-06-08 SG SG10201913536TA patent/SG10201913536TA/en unknown
- 2018-06-08 MX MX2019015021A patent/MX2019015021A/es unknown
- 2018-06-11 US US16/005,088 patent/US20190002589A1/en not_active Abandoned
-
2019
- 2019-10-14 ZA ZA2019/06757A patent/ZA201906757B/en unknown
- 2019-12-04 IL IL271179A patent/IL271179A/en unknown
- 2019-12-10 CO CONC2019/0013838A patent/CO2019013838A2/es unknown
- 2019-12-10 CL CL2019003613A patent/CL2019003613A1/es unknown
- 2019-12-10 EC ECSENADI201987580A patent/ECSP19087580A/es unknown
-
2020
- 2020-04-09 US US16/844,999 patent/US20200308309A1/en active Pending
-
2021
- 2021-07-20 AU AU2021206810A patent/AU2021206810A1/en active Pending
-
2022
- 2022-05-11 JP JP2022078272A patent/JP2022116038A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR112419A1 (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
AR111418A1 (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
CL2018000461A1 (es) | Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador. | |
AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
CO2020010345A2 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
PE20180188A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales | |
EA201990285A1 (ru) | Гетеродимерные иммуноглобулиновые конструкции и способы их получения | |
EA201691925A1 (ru) | Биспецифические антитела, которые связываются с cd38 и cd3 | |
PE20091172A1 (es) | Anticuerpos bivalentes biespecificos | |
PE20171324A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales | |
EA201990894A1 (ru) | Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения | |
PE20190514A1 (es) | Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123 | |
ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
WO2015033223A3 (en) | Readily isolated bispecific binding molecules with native format having mutated constant regions | |
EA202091888A1 (ru) | Вариабельные домены антител, нацеленные на рецептор nkg2d | |
PE20191031A1 (es) | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS | |
PE20221282A1 (es) | Anticuerpos que se unen a hla-a2/mage-a4 | |
AR114102A1 (es) | Anticuerpo biespecífico heterodimérico estructural natural anti-pd-1 / anti-her2 y método para su preparación | |
CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
MX2020013606A (es) | Constructos de anticuerpos multiespecificos. | |
PE20221316A1 (es) | Proteinas que se unen a nkg2d, cd16 y flt3 | |
EA202290208A1 (ru) | МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ EGFRvIII, И ИХ ПРИМЕНЕНИЕ | |
AR119382A1 (es) | Anticuerpos de pre-direccionamiento y métodos de uso | |
AR124609A1 (es) | Anticuerpos divididos y métodos de uso |